The document provides an overview of the global therapeutic pipeline for uveal melanoma as of the first half of 2015. It details the various drugs and therapies under investigation by companies and research institutions to treat uveal melanoma. Key players in this field are identified and individual drug profiles are included summarizing each treatment's description, mechanism of action, and development progress. The report aims to help decision making and research strategies regarding uveal melanoma therapeutic development.

1. Uveal Melanoma - Pipeline Review, H1 2015
Global Markets Directs, Uveal Melanoma Pipeline Review, H1 2015, provides an overview of the Uveal Melanomas therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Uveal Melanoma, complete with comparative analysis at various stages,
therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured
news and press releases. It also reviews key players involved in the therapeutic development for Uveal Melanoma and special features on late-stage and
discontinued projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built
using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and
featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug
profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the
latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that
the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by
identifying new targets and MOAs to produce first-in-class and best-in-class products.
Scope
The report provides a snapshot of the global therapeutic landscape of Uveal Melanoma The report reviews key pipeline products under drug profile section
which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities The report reviews key players
involved in the therapeutics development for Uveal Melanoma and enlists all their major and minor projects The report summarizes all the dormant and
discontinued pipeline projects A review of the Uveal Melanoma products under development by companies and universities/research institutes based on
information derived from company and industry-specific sources Pipeline products coverage based on various stages of development ranging from
pre-registration till discovery and undisclosed stages A detailed assessment of monotherapy and combination therapy pipeline projects Coverage of the Uveal
Melanoma pipeline on the basis of target, MoA, route of administration and molecule type Latest news and deals relating related to pipeline products
Reasons to buy
Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies Identify emerging players
with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage Develop strategic initiatives by understanding the
focus areas of leading companies Identify and understand important and diverse types of therapeutics under development for Uveal Melanoma Plan mergers and
acquisitions effectively by identifying key players of the most promising pipeline Devise corrective measures for pipeline projects by understanding Uveal
Melanoma pipeline depth and focus of Indication therapeutics Develop and design in-licensing and out-licensing strategies by identifying prospective partners
with the most attractive projects to enhance and expand business potential and scope Modify the therapeutic portfolio by identifying discontinued projects and
understanding the factors that drove them from pipeline
table Of Contents
table Of Contents 2
list Of Tables 4
list Of Figures 5
introduction 6
global Markets Direct Report Coverage 6
uveal Melanoma Overview 7
therapeutics Development 8
pipeline Products For Uveal Melanoma - Overview 8
pipeline Products For Uveal Melanoma - Comparative Analysis 9
uveal Melanoma - Therapeutics Under Development By Companies 10
uveal Melanoma - Therapeutics Under Investigation By Universities/institutes 11
uveal Melanoma - Pipeline Products Glance 12
late Stage Products 12
clinical Stage Products 13
early Stage Products 14
uveal Melanoma - Products Under Development By Companies 15
uveal Melanoma - Products Under Investigation By Universities/institutes 16
uveal Melanoma - Companies Involved In Therapeutics Development 17
array Biopharma Inc. 17
astrazeneca Plc 18
celldex Therapeutics, Inc. 19
eli Lilly And Company 20
glaxosmithkline Plc 21
novartis Ag 22
pfizer Inc. 23
spectrum Pharmaceuticals, Inc. 24
uveal Melanoma - Therapeutics Assessment 25
assessment By Monotherapy Products 25
Uveal Melanoma - Pipeline Review, H1 2015

2. assessment By Combination Products 26
assessment By Target 27
assessment By Mechanism Of Action 29
assessment By Route Of Administration 31
assessment By Molecule Type 33
drug Profiles 35
binimetinib - Drug Profile 35
product Description 35
mechanism Of Action 35
r&d Progress 35
crizotinib - Drug Profile 40
product Description 40
mechanism Of Action 40
r&d Progress 40
dendritic Cell Therapy To Target Melan-a, Mage-3 And Survivin For Melanoma And Uveal Melanoma - Drug Profile 43
product Description 43
mechanism Of Action 43
r&d Progress 43
emibetuzumab - Drug Profile 44
product Description 44
mechanism Of Action 44
r&d Progress 44
glembatumumab Vedotin - Drug Profile 45
product Description 45
mechanism Of Action 45
r&d Progress 45
merestinib - Drug Profile 47
product Description 47
mechanism Of Action 47
r&d Progress 47
nutlin-3 - Drug Profile 48
product Description 48
mechanism Of Action 48
r&d Progress 48
pasireotide Lar - Drug Profile 49
product Description 49
mechanism Of Action 49
r&d Progress 49
selumetinib Sulfate - Drug Profile 51
product Description 51
mechanism Of Action 51
r&d Progress 51
sotrastaurin Acetate - Drug Profile 54
product Description 54
mechanism Of Action 54
r&d Progress 54
sunitinib Malate - Drug Profile 56
product Description 56
mechanism Of Action 56
r&d Progress 56
trametinib Dimethyl Sulfoxide + Uprosertib - Drug Profile 60
product Description 60
mechanism Of Action 60
r&d Progress 60
vincristine Sulfate - Drug Profile 62
product Description 62
mechanism Of Action 62
r&d Progress 62
uveal Melanoma - Recent Pipeline Updates 65
uveal Melanoma - Dormant Projects 83
uveal Melanoma - Product Development Milestones 84
featured News & Press Releases 84
jun 01, 2013: Astrazeneca's New Therapy Selumetinib Improves Progression-free Survival And Shrink Tumors In Metastatic Uveal Melanoma, Researchers
Report 84
appendix 85
methodology 85
Uveal Melanoma - Pipeline Review, H1 2015

3. coverage 85
secondary Research 85
primary Research 85
expert Panel Validation 85
contact Us 85
disclaimer 86
ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your
research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and
across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an
informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
Contact:
Sales Team,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-997-4948
Email: sales@researchmoz.us
Website: http://www.researchmoz.us/
Uveal Melanoma - Pipeline Review, H1 2015